Immix Biopharma Appoints Dual SVPs to Lead CMC and Regulatory Affairs

With a BLA submission targeted for mid-2027, Immix Biopharma is structuring its technical operations and regulatory affairs functions now, a sequencing decision that carries direct implications for CMC readiness timelines across the broader CAR-T commercialization pipeline.

The company has appointed David He, MD, PhD as Senior Vice President, Head of Technical Operations. He brings direct pre-BLA and commercial-stage CMC experience from two approved BCMA CAR-T therapies, CARVYKTI and FUCASO, and previously served as Chief Technology Officer at IASO Biotherapeutics and Vice President, Technical Operations at Legend Biotech. His mandate at Immix covers chemistry, manufacturing, and controls for NXC-201, the company's investigational CAR-T for relapsed/refractory AL amyloidosis.

Separately, Immix has appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs. McIntosh's regulatory dossier includes FDA and EMA submissions for JANUVIA, EMFLAZA, ELZONRIS, and the 2026 FDA approval of TREGZI. She joins from Orca Bio, where she held the equivalent VP-level regulatory role, and previously held senior positions at Stemline Therapeutics, PTC Therapeutics, Merck, and Pfizer. Her scope at Immix spans U.S. and global regulatory strategy.

The appointments land against a clinical backdrop that strengthens the BLA rationale. Across all 45 NEXICART-2 patients, NXC-201 has produced an 89% complete response rate, with MRD-negativity data suggesting a potential ceiling of 98%. Interim results are scheduled for oral presentation at the 68th ASH Annual Meeting on December 14, 2026, in New Orleans, a visibility moment that typically accelerates payer and provider engagement timelines for pre-commercial cell therapy programs.

For QA directors and regulatory leads tracking cell therapy precedents, the operational model here is notable: Immix is running commercial site activation, payer engagement, and healthcare professional education in parallel with CMC buildout, rather than sequentially. The company also confirmed initiation of the NEXICART-3 frontline trial in the first half of 2027, which will extend the regulatory affairs workload beyond the initial BLA cycle.

Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, with operating expenses of $15.9 million for Q3, a runway the company projects extends into mid-2028, providing a financial buffer that covers the BLA submission window and early post-approval activities.

The mid-2027 BLA filing date now functions as the primary scheduling anchor for CMC package completion, process validation sign-off, and regulatory submission readiness across Immix's technical and quality teams.

Source: Immix Biopharma via GlobeNewswire, November 12, 2026.